Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ABT +2.5%, WTFC +2%, MTB +2%, HWC +1.5%, PG +1.5%, GBDC +1.4%, FULT +1.4%, ELV +1.2%
Other news:
- ARDX +16.8% (receives FDA approval for XPHOZAH; amends debt financing agreement with SLR Capital Partners to provide $50 million of additional committed capital)
- CDT +9.2% (stock offering by selling shareholders)
- FND +9.1% (to join S&P MidCap 400)
- FRLN +8.8% (Majority shareholder Syncona files amended 13D; submitted acquisition proposal for outstanding shares)
- VKTX +8.4% (new results from trial of VK2735 featured in oral presentation)
- SAGE +4.7% (announces FDA granted SAGE-718 orphan drug designation for the treatment of huntington's disease)
- TALS +3.9% (receives stockholder approval of merger with Tourmaline Bio)
- FREY +3.5% (provides Redomiciliation updates; anticipates that the Redomiciliation Transaction will become effective in the fourth quarter of 2023)
- CCO +3.4% (signs share purchase agreement to sell its France Business to Equinox Industries)
- NTLA +1.6% (FDA has cleared its Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy)
- WDS +1.3% (provides Q3 update; narrows FY23 production guidance)
Analyst comments:
- HUN +2% (upgraded to Buy from Underperform at BofA Securities)
- LYB +1.5% (upgraded to Neutral from Underperform at BofA Securities)
- DOW +1% (upgraded to Neutral from Underperform at BofA Securities)